296 related articles for article (PubMed ID: 14520860)
21. HyperCVAD for VAD-resistant multiple myeloma.
Dimopoulos MA; Weber D; Kantarjian H; Delasalle KB; Alexanian R
Am J Hematol; 1996 Jun; 52(2):77-81. PubMed ID: 8638645
[TBL] [Abstract][Full Text] [Related]
22. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J
Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of multiple myeloma resistant to alkylating agents with dexamethasone, vincristine and adriamycin in continuous infusion].
Monconduit M; Le Loët X; Bernard JF; Menard JF; Grosbois B; Michaux JL; De Gramont A; Laporte JP; Najman A; Jouet JP
Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):477-9. PubMed ID: 3616472
[No Abstract] [Full Text] [Related]
24. [Pneumonia caused by Salmonella in a patient with myeloma].
Fernández P; Roldán V; García MC; Gil MT; Rivas C
Sangre (Barc); 1995 Jun; 40(3):234-5. PubMed ID: 7570286
[No Abstract] [Full Text] [Related]
25. Regression of gastroduodenal amyloid deposition in systemic AL amyloidosis after intensive chemotherapies.
Katoh N; Matsuda M; Tsuchiya-Suzuki A; Ikeda S
Br J Haematol; 2011 May; 153(4):535-8. PubMed ID: 21275957
[No Abstract] [Full Text] [Related]
26. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
27. Is granulocyte-macrophage colony-stimulating factor (GM-CSF) safe in myelodysplastic syndromes?
Mittelman M; Floru S; Pick AI
Haematologia (Budap); 1994; 26(2):111-5. PubMed ID: 7890261
[TBL] [Abstract][Full Text] [Related]
28. [Lower cardiotoxicity of adriamycin during continuous administration in patients with refractory multiple myeloma treated with cyclophosphamide, vincristine, adriamycin and dexamethasone (C-VAD)].
Adam Z; Elbl L; Vorlícek J; Hájek R; Tomíska M; Hejlová N; Králová E; Novotná H
Vnitr Lek; 1994 Aug; 40(8):506-12. PubMed ID: 7941437
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
30. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
31. Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis.
Katagiri D; Hagiwara S; Minami E; Katsuma A; Masumoto S; Hoshino T; Inoue T; Shibata M; Tada M; Nakamura T; Shimbo T; Hinoshita F
Nephron Clin Pract; 2011; 117(1):c28-32. PubMed ID: 20689322
[TBL] [Abstract][Full Text] [Related]
32. The treatment of multiple myeloma.
Alexanian R; Dimopoulos M
N Engl J Med; 1994 Feb; 330(7):484-9. PubMed ID: 8289856
[No Abstract] [Full Text] [Related]
33. Distinct patterns of chromonychia, Beau's lines, and melanoderma seen with vincristine, adriamycin, dexamethasone therapy for multiple myeloma.
Dasanu CA; Vaillant JG; Alexandrescu DT
Dermatol Online J; 2006 Oct; 12(6):10. PubMed ID: 17083890
[TBL] [Abstract][Full Text] [Related]
34. Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Yang X; Yang C; Shao K; Ye X; Meng H; Zhou Y; Qian W
Ann Hematol; 2007 Dec; 86(12):919-21. PubMed ID: 17641891
[No Abstract] [Full Text] [Related]
35. Transient severe symptomatic pulmonary hypertension as onset symptom in multiple myeloma.
Rostagno C; Ciolli S
Ann Hematol; 2006 Sep; 85(9):627-8. PubMed ID: 16705455
[No Abstract] [Full Text] [Related]
36. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
38. Malignant myelomatous pleural effusion with good response to combination chemotherapy.
Attili VS; Singh VP; Sundar S; Mehta H; Negi ML; Gogia A; Raju SH; Rai M
J Assoc Physicians India; 2007 Aug; 55():595-6. PubMed ID: 18019805
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules.
Cesana C; Nosari AM; Klersy C; Miqueleiz S; Rossi V; Ferrando P; Valentini M; Barbarano L; Morra E
Haematologica; 2003 Sep; 88(9):1022-8. PubMed ID: 12969810
[TBL] [Abstract][Full Text] [Related]
40. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
